IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-day grace period until January 14, 2025, to regain compliance. During this period, ICCM's shares will continue trading on the Nasdaq Capital Market.

To regain compliance, ICCM's closing bid price must be at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period, provided it meets other listing requirements. IceCure Medical states that maintaining its Nasdaq listing is a priority and will consider available options to cure the deficiency if necessary.

Positive

• Granted 180-day grace period to regain compliance with Nasdaq's minimum bid price requirement
• Shares continue to trade on Nasdaq Capital Market during the compliance period
• Possibility of additional 180-day compliance period if initial period is unsuccessful

Negative

• Non-compliance with Nasdaq's minimum bid price requirement of $1.00 per share
• Risk of delisting from Nasdaq if compliance is not achieved within the given timeframe

CAESAREA, Israel, July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "ICCM".

According to the Notice, the Company has until January 14, 2025, to regain compliance with the minimum bid price requirement. The Company can regain compliance if at any time during this 180-day period the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be closed.

In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.

The Company intends to monitor the closing bid price of its ordinary shares and its continued listing on Nasdaq is a priority for the Company. Should the situation not resolve itself over the above-mentioned time frame, the Company intends to consider available options to cure the deficiency and regain compliance with the minimum bid price requirement within the compliance period.

About IceCure Medical Ltd.

IceCure Medical Ltd. (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and China.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when it discusses regaining compliance with Nasdaq's continued listing requirements, and timing and effect thereof. Because such actions deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of the Company could differ materially from those described in or implied by the statements in this press release. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC") on April 3, 2024, and in subsequent filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

IR Contact:

Email: investors@icecure-medical.com

Michael Polyviou

Phone: 732-232-6914

Todd Kehrli

Phone: 310-625-4462

Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification-302201447.html

SOURCE IceCure Medical

FAQ

What is the minimum bid price requirement IceCure Medical (ICCM) must meet for Nasdaq compliance?

IceCure Medical (ICCM) must maintain a minimum bid price of $1.00 per share to comply with Nasdaq's listing requirements.

When is the deadline for IceCure Medical (ICCM) to regain compliance with Nasdaq's minimum bid price requirement?

IceCure Medical (ICCM) has until January 14, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

How can IceCure Medical (ICCM) regain compliance with Nasdaq's minimum bid price requirement?

IceCure Medical (ICCM) can regain compliance if its closing bid price is at least $1.00 for a minimum of ten consecutive business days during the 180-day grace period.

What happens if IceCure Medical (ICCM) fails to meet Nasdaq's minimum bid price requirement within the initial grace period?

If IceCure Medical (ICCM) fails to meet the requirement within the initial period, it may be eligible for an additional 180-day compliance period if it meets other listing standards.